AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19543005 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 14
Study 19543005 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 14
Study 17292948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg bid
Number of subjects: 625
Study 17292948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg bid
Number of subjects: 625
Study 17292948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg bid
Number of subjects: 625
Study 17292948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg bid
Number of subjects: 625
Study 17292948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg bid
Number of subjects: 625
Study 17292948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg od
Number of subjects: 625
Study 17292948 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg od
Number of subjects: 625
Study 17292948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (all doses)
Number of subjects: 625
Study 17292948 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 625
Study 15355132 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based training
Number of subjects: 0
Study 15355132 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-based training
Number of subjects: 0
Study 15355132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of training
Number of subjects: 0
Study 11231430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 60 IU/kg IV during PCI
Number of subjects: 59
Study 11231430 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin 40 IU/kg IV during PCI
Number of subjects: 59
Study 9728784 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with tinzaparin for four weeks (n = 58)
Number of subjects: 118
Study 9728784 — intervention group
Group type: COMPARATOR
Intervention: Control group with thromboprophylaxis for one week (n = 60)
Number of subjects: 118
Study 8299092 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus melatonin (20 mg/day at 8:00 p.m. orally)
Number of subjects: 50
Study 8299092 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone (steroids plus anticonvulsant agents)
Number of subjects: 50
Study 3142634 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxythiolin irrigation (2.5% solution)
Number of subjects: 20
Study 3142634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 4533699 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2alpha (PGF2alpha) with oxytocin
Number of subjects: 32
Study 4533699 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (20%) with oxytocin
Number of subjects: 32
Study 30578714 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to a protocol for precursor lymphoblastic lymphoma
Number of subjects: 11
Study 28895220 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiding Stars system (intervention supermarkets)
Number of subjects: 783
Study 28895220 — intervention group
Group type: COMPARATOR
Intervention: Control supermarkets
Number of subjects: 783
Study 25854692 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access and bivalirudin
Number of subjects: 0
Study 25854692 — intervention group
Group type: COMPARATOR
Intervention: Femoral access (control group)
Number of subjects: 0
Study 23625531 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 173
Study 23625531 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins/minerals
Number of subjects: 173
Study 23625531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 23625531 — intervention group
Group type: EXPERIMENTAL
Intervention: Both (DHA and multivitamins/minerals)
Number of subjects: 173
Study 21853854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent GVS at 3.5 mA or 5 mA
Number of subjects: 60
Study 21853854 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous GVS at 3.5 mA or 5 mA
Number of subjects: 60
Study 19860889 — intervention group
Group type: EXPERIMENTAL
Intervention: D-aspartate (DADAVIT) for 12 days in humans (23 men)
Number of subjects: 33
Study 19860889 — intervention group
Group type: EXPERIMENTAL
Intervention: D-aspartate (20 mM solution) for 12 days in rats (10 rats)
Number of subjects: 33
Study 19860889 — intervention group
Group type: EXPERIMENTAL
Intervention: D-aspartate in rat pituitary
Number of subjects: 33
Study 19860889 — intervention group
Group type: EXPERIMENTAL
Intervention: D-aspartate in rat Leydig cells
Number of subjects: 33
Study 19860889 — intervention group
Group type: COMPARATOR
Intervention: Placebo in humans (20 men)
Number of subjects: 33
Study 19860889 — intervention group
Group type: COMPARATOR
Intervention: Placebo in rats
Number of subjects: 33
Study 16901286 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (40 kDa) plus ribavirin for 24 weeks
Number of subjects: 117
Study 16901286 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (40 kDa) plus ribavirin for 48 weeks
Number of subjects: 117
Study 15641601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at MAC 1
Number of subjects: 80
Study 15641601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at MAC 1.5
Number of subjects: 80
Study 15641601 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 80
Study 15641601 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80
Study 10910868 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional intubation with propofol (median dose: 2.74 +/- 1.59 mg/kg; range 1.95-7.07 mg/kg)
Number of subjects: 32
Study 10910868 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic intubation with propofol (median dose: 1.37 +/- 0.59 mg/kg; range 0.72-2.86 mg/kg)
Number of subjects: 32
Study 10910868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (conventional and fiberoptic)
Number of subjects: 32
Study 10910868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 8632935 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5% energy as 60:40 whey:casein protein
Number of subjects: 0
Study 8632935 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.7% energy as 60:40 whey:casein protein
Number of subjects: 0
Study 8632935 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0% energy as 60:40 whey:casein protein
Number of subjects: 0
Study 8632935 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.7% protein for toddlers
Number of subjects: 0
Study 8632935 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% protein for toddlers
Number of subjects: 0
Study 8632935 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0% protein for toddlers
Number of subjects: 0
Study 1484577 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA treatment before operation
Number of subjects: 757
Study 1484577 — intervention group
Group type: COMPARATOR
Intervention: No EACA treatment
Number of subjects: 757
Study 3933890 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma‐L‐Glutamyl‐L‐dopa at 12.5 micrograms min‐1 kg‐1
Number of subjects: 8
Study 3933890 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma‐L‐Glutamyl‐L‐dopa at 100 micrograms min‐1 kg‐1
Number of subjects: 8
Study 30268859 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited screening plus FDG PET/CT scan
Number of subjects: 394
Study 30268859 — intervention group
Group type: COMPARATOR
Intervention: Limited screening
Number of subjects: 394
Study 30268859 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive screening
Number of subjects: 394
Study 28314743 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucloxacillin with clindamycin
Number of subjects: 410
Study 28314743 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin alone
Number of subjects: 410
Study 25297900 — intervention group
Group type: EXPERIMENTAL
Intervention: Unifocal tumors
Number of subjects: 6134
Study 25297900 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal tumors
Number of subjects: 6134
Study 25297900 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicentric tumors
Number of subjects: 6134
Study 25297900 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved pCR or breast conservation after NACT
Number of subjects: 6134
Study 23177180 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution
Number of subjects: 1655
Study 23177180 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1655
Study 20947098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone treatment during relapse
Number of subjects: 0
Study 20947098 — intervention group
Group type: COMPARATOR
Intervention: CSF concentrations of CXCL13
Number of subjects: 0
Study 20947098 — intervention group
Group type: COMPARATOR
Intervention: Serum CCL20 levels
Number of subjects: 0
Study 20947098 — intervention group
Group type: COMPARATOR
Intervention: CCL17 and CCL20 detection in CSF
Number of subjects: 0
Study 20947098 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CXCL13 and CCL20 levels
Number of subjects: 0
Study 18641371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo/Cuff
Number of subjects: 60
Study 18641371 — intervention group
Group type: COMPARATOR
Intervention: KoldBlue
Number of subjects: 60
Study 17186737 — intervention group
Group type: EXPERIMENTAL
Intervention: Qidi Yiqi Yangyin Huoxue Recipe (QYYHR)
Number of subjects: 100
Study 17186737 — intervention group
Group type: COMPARATOR
Intervention: Basal hypoglycemic treatment (Control)
Number of subjects: 100
Study 14617116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine and ketamine before propofol infusion
Number of subjects: 122
Study 14617116 — intervention group
Group type: COMPARATOR
Intervention: Atropine, normal saline solution, and a mixture of propofol with lidocaine
Number of subjects: 122
Study 10709427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nafarelin acetate (NA) 800 micrograms/d
Number of subjects: 88
Study 10709427 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate (LA) 0.5 mg/d
Number of subjects: 88
Study 7554554 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (Cs)
Number of subjects: 52
Study 7554554 — intervention group
Group type: COMPARATOR
Intervention: Control group (RA patients not on Cs)
Number of subjects: 52
Study 1682739 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 15
Study 1682739 — intervention group
Group type: COMPARATOR
Intervention: Concomitant treatment with 300 mg aspirin daily
Number of subjects: 15
Study 7019929 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg glucosamine sulphate (injectable)
Number of subjects: 30
Study 7019929 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucosamine capsules (6 x 250 mg daily)
Number of subjects: 30
Study 7019929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 30
Study 7019929 — intervention group
Group type: COMPARATOR
Intervention: Piperazine/chlorbutanol combination (intravenous or intramuscular)
Number of subjects: 30
Study 31677590 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% (130/0.4)
Number of subjects: 55
Study 31677590 — intervention group
Group type: COMPARATOR
Intervention: Albumin 5%
Number of subjects: 55
Study 27799322 — intervention group
Group type: EXPERIMENTAL
Intervention: Head cooling for 72 hours starting within 6 hours of birth
Number of subjects: 194
Study 27799322 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 194
Study 26133971 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg of body mass)
Number of subjects: 8
Study 26133971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 8
Study 24694926 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg)
Number of subjects: 13
Study 24694926 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (0.75 mg/kg)
Number of subjects: 13
Study 24694926 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg)
Number of subjects: 13
Study 24694926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 24694926 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (0.75 mg/kg) and MDMA (1.5 mg/kg)
Number of subjects: 13
Study 22710356 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot (BR) beverage, 500 ml daily for 6 days
Number of subjects: 14
Study 22710356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL), 500 ml daily for 6 days
Number of subjects: 14
Study 19686592 — intervention group
Group type: EXPERIMENTAL
Intervention: TetraVisc 0.5% (0.5 ml)
Number of subjects: 122
Study 19686592 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% gel (1 ml)
Number of subjects: 122
Study 17653981 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose corn syrup (HFCS) consumption
Number of subjects: 0
Study 17653981 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiologic studies and randomized controlled trials
Number of subjects: 0
Study 17653981 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCS and sucrose consumption
Number of subjects: 0
Study 17653981 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose corn syrup (HFCS)
Number of subjects: 0
Study 15666940 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement Goal Priming
Number of subjects: 66
Study 15666940 — intervention group
Group type: COMPARATOR
Intervention: Neutral Priming
Number of subjects: 66
Study 15666940 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Monitoring (task presented as a measure of ability)
Number of subjects: 66
Study 12226017 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate via HFA‐134a pMDI
Number of subjects: 47
Study 12226017 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate via Diskhaler
Number of subjects: 47
Study 12226017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 9845649 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming blanket
Number of subjects: 100
Study 9845649 — intervention group
Group type: COMPARATOR
Intervention: Circulating water mattress
Number of subjects: 100
Study 9845649 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (temperature less than 36 degrees C)
Number of subjects: 100
Study 9845649 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic aneurysm patients
Number of subjects: 100
Study 10210927 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (500 micrograms two times a day subcutaneous for six months)
Number of subjects: 6
Study 10210927 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 6
Study 10210927 — intervention group
Group type: COMPARATOR
Intervention: Control (supportive care)
Number of subjects: 6
Study 1763797 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous quinine (20 mg salt/kg loading, then 10 mg salt/kg every 12 hr)
Number of subjects: 59
Study 1763797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular quinine (20 mg salt/kg loading, then 10 mg salt/kg every 12 hr)
Number of subjects: 59
Study 1763797 — intervention group
Group type: COMPARATOR
Intervention: Low-dose intravenous quinine (10 mg salt/kg loading, then 5 mg salt/kg every 12 hr)
Number of subjects: 59
Study 7037043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 litre of 10% (w/v) glucose intravenously over 1 h
Number of subjects: 3
Study 7037043 — intervention group
Group type: COMPARATOR
Intervention: 1 litre of 0.9% sodium chloride solution intravenously over 1 h
Number of subjects: 3
Study 7037043 — intervention group
Group type: COMPARATOR
Intervention: No supplementary infusion
Number of subjects: 3
Study 31649028 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ESP blocks with 20 mL 0.5% ropivacaine
Number of subjects: 54
Study 31649028 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM) 400 µg
Number of subjects: 54
Study 31649028 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ESP blocks
Number of subjects: 54
Study 31649028 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM)
Number of subjects: 54
Study 28270292 — intervention group
Group type: COMPARATOR
Intervention: 70 kV group
Number of subjects: 82
Study 25319074 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 73
Study 25319074 — intervention group
Group type: COMPARATOR
Intervention: VMP chemotherapy
Number of subjects: 73
Study 24192073 — intervention group
Group type: EXPERIMENTAL
Intervention: Power brushing
Number of subjects: 175
Study 24192073 — intervention group
Group type: COMPARATOR
Intervention: Manual brushing
Number of subjects: 175
Study 24192073 — intervention group
Group type: EXPERIMENTAL
Intervention: Power brushing and Manual brushing
Number of subjects: 175
Study 21457539 — intervention group
Group type: COMPARATOR
Intervention: Anthelmintic treatment
Number of subjects: 0
Study 18073313 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine/GHRH
Number of subjects: 22
Study 18073313 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH/GHRP-2
Number of subjects: 22
Study 18073313 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine/GHRP-2
Number of subjects: 22
Study 18073313 — intervention group
Group type: COMPARATOR
Intervention: Integrated GH responses
Number of subjects: 22
Study 17066505 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine-HCl 37.5 mg once daily with behavioral therapy
Number of subjects: 68
Study 17066505 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily with behavioral therapy
Number of subjects: 68
Study 12957347 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 405
Study 12957347 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 405
Study 10853298 — intervention group
Group type: EXPERIMENTAL
Intervention: FA-specific IgE antibody measurement
Number of subjects: 80
Study 10853298 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgE measurement
Number of subjects: 80
Study 10853298 — intervention group
Group type: EXPERIMENTAL
Intervention: sECP measurement
Number of subjects: 80
Study 10853298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function tests (FEV1%, %VC, V25/HT)
Number of subjects: 80
Study 8704111 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol NaCl/day)
Number of subjects: 61
Study 8704111 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (320 mmol NaCl/day)
Number of subjects: 61
Study 8704111 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch from high to low sodium intake
Number of subjects: 61
Study 8704111 — intervention group
Group type: COMPARATOR
Intervention: Baseline active kallikrein excretion
Number of subjects: 61
Study 1793331 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 or 4 mg)
Number of subjects: 125
Study 1793331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 6133000 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g SASP daily
Number of subjects: 391
Study 6133000 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 2, or 4 g SASP daily for 6 months
Number of subjects: 391
Study 6133000 — intervention group
Group type: COMPARATOR
Intervention: 20 mg prednisolone daily for one week
Number of subjects: 391
Study 6133000 — intervention group
Group type: COMPARATOR
Intervention: Dummy tablets for one week
Number of subjects: 391
Study 30888989 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐6DIG
Number of subjects: 11
Study 30176051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparous women
Number of subjects: 206
Study 30176051 — intervention group
Group type: EXPERIMENTAL
Intervention: Parous women
Number of subjects: 206
Study 26837684 — intervention group
Group type: EXPERIMENTAL
Intervention: BDD-NET (n=47)
Number of subjects: 94
Study 26837684 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (n=47)
Number of subjects: 94
Study 25139539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 25139539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22464259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg
Number of subjects: 160
Study 22464259 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 160
Study 22464259 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 160
Study 22464259 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 80 mg
Number of subjects: 160
Study 20387351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Number of subjects: 423
Study 20387351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 423
Study 20387351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 17621520 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium bromide (started at 45 mg/kg, raised to 70 mg/kg)
Number of subjects: 113
Study 15981008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (0.3 ml, 7,500 anti-Xa units)
Number of subjects: 2474
Study 15981008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2474
Study 15981008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 2474
Study 12560610 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment strategy according to American College of Cardiology / American Heart Association practice guidelines (2002)
Number of subjects: 0
Study 9808394 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid elemental peptide diet for four weeks
Number of subjects: 30
Study 9808394 — intervention group
Group type: COMPARATOR
Intervention: Continuation of usual food (control group)
Number of subjects: 30
Study 8742865 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 70 mg.kg‐1 body mass per day mixed with 5 g glucose)
Number of subjects: 17
Study 8742865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 x 10 g glucose per day)
Number of subjects: 17
Study 2506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at 0.25 micrograms/kg/min
Number of subjects: 10